Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham

The Life Sciences Report: Geoff, what is your current theme? Geoff Meacham: We were very bullish on the biotech group in 2010 and 2011. Fundamentals are still very good, but I would say we’re more cautious on the performance of the group for all of 2012. One of the things we pointed out in our 2012 Global Biotech Outlook is that the tone of the group before 2012, literally last fall, was very negative. We offered a couple of ideas of what could change the sentiment very positively. It turns out that a lot of that stuff actually happened. Deals happened like the Bristol-Myers Squibb (BMY:NYSE) $2.5 billion (B) acquisition of Inhibitex Inc. (INHX:NASDAQ). That caused a lot of . . . → Read More: Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham